Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C By Watertime - August 18, 2026 4 Post Content RELATED ARTICLESMORE FROM AUTHOR Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD Pα+ Library: Psychedelic REMS The Best Psychedelic Education Does Not Look Psychedelic